Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 3Pancreatic Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Recurrence 1Pre-menopausal Breast Cancer 1Neoplasms 1Lung Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 3fludarabine 2Paclitaxel 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1temsirolimus 1spartalizumab 1sonidegib 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1ridaforolimus 1pazopanib 1motexafin gadolinium 1lenvatinib 1durvalumab 1depatuxizumab mafodotin 1cediranib 1cc-486 1carboxyamido-triazole 1abiraterone 1Thalidomide 1Temozolomide 1Sorafenib 1Sirolimus 1Radiation 1Quality of Life 1Proton Pump Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × NVP-BKM120 × Breast × Clear all
NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
120 enrolled
BreastCNSGastrointestinal

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡